No­vo-Catal­ent deal like­ly to be one-off — with some caveats, in­sid­ers say

An ac­qui­si­tion sim­i­lar to No­vo Hold­ings’ pro­posed $16.5 bil­lion buy for Catal­ent is un­like­ly to hap­pen again be­cause it bucks the trend of phar­ma com­pa­nies …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.